Findings

What do systematic reviews say?

Refine by population, intervention, comparison or outcome
More filters
Evidence found and GRADE certainty

3,097 questions · 3,266 findings · 631 reviews

No studies found 430 · 13.2%GRADE not reported 193 · 5.9%Very low 995 · 30.5%Low 904 · 27.7%Moderate 591 · 18.1%High 153 · 4.7%

Ultrasound guidance vs landmark method

Patient satisfaction NRS from 0 to 10 or 4‐step Likert scale The higher the score, the higher the level of satisfaction · adults undergoing peripheral venous cannulation classed as moderately difficulta

The review found no eligible studies for this question.

1 finding from 1 review

Tocilizumab weekly vs placebo + 52‐week taper

Mean change in VAS (higher scores suggest greater disease activity and worse quality of life) at ≥ 12 months · adults aged over 50 years with giant cell arteritis

Tocilizumab weekly showed no clear difference in mean change in VAS (higher scores suggest greater disease activity… compared with placebo + 52‐week taper (moderate certainty).

1 finding from 1 review

Tocilizumab weekly vs placebo + 26‐week taper

Mean change in VAS (higher scores suggest greater disease activity and worse quality of life) at ≥ 12 months · adults aged over 50 years with giant cell arteritis

Tocilizumab weekly showed no clear difference in mean change in VAS (higher scores suggest greater disease activity… compared with placebo + 26‐week taper (moderate certainty).

1 finding from 1 review

Tocilizumab every other week vs placebo + 52‐week taper

Mean change in VAS (higher scores suggest greater disease activity and worse quality of life) at ≥ 12 months · adults aged over 50 years with giant cell arteritis

Tocilizumab every other week showed no clear difference in mean change in VAS (higher scores suggest greater disease activity… compared with placebo + 52‐week taper (moderate certainty).

1 finding from 1 review

Tocilizumab every other week vs placebo + 26‐week taper

Mean change in VAS (higher scores suggest greater disease activity and worse quality of life) at ≥ 12 months · adults aged over 50 years with giant cell arteritis

Tocilizumab every other week showed no clear difference in mean change in VAS (higher scores suggest greater disease activity… compared with placebo + 26‐week taper (moderate certainty).

1 finding from 1 review

Tocilizumab every 4 weeks vs placebo

Mean change in VAS (higher scores suggest greater disease activity and worse quality of life) at ≥ 12 months · adults aged over 50 years with giant cell arteritis

The review found no eligible studies for this question.

1 finding from 1 review

Any intervention vs steroid alone or plus levofloxacin

Proportion of participants who discontinued medication and did not develop rebound SEI within 21 days (higher is favored) · epidemic keratoconjunctivitis

It is very uncertain whether any intervention changes proportion of participants who discontinued medication and did not… compared with steroid alone or plus levofloxacin (very low certainty).

1 finding from 1 review